Cutaneous manifestations in Egyptian children with beta‐thalassemia major: Relationship with serum ferritin, thyroid profile, and treatment modalities
Authors:
- 26 June 2018
- journal article
- research article
- Published by Wiley in Pediatric Dermatology
- Vol. 35 (5) , 639-643
Abstract
Background: Cutaneous manifestations can be found in many patients with hematologic disorders, including thalassemia.Methods: Patients with beta‐thalassemia major attending the pediatric department of Fayoum University Hospital from April 2016 to October 2016 (n = 100) were compared with controls (n = 100). Both groups underwent detailed history evaluation, clinical examination, and laboratory investigations, including complete blood count, liver and kidney function, serum ferritin, and thyroid profile. A single dermatologist conducted a clinical dermatologic examination for all participants.Results: Children with thalassemia had a greater prevalence of xerosis (72%), pruritus (52%), idiopathic guttate hypomelanosis (22%), urticaria (16%), ephelides (freckles; 13%), and scars (13%) than controls (P ≤ .001). We detected a significant relationship between serum ferritin and pruritus, xerosis, ephelides, idiopathic guttate hypomelanosis, urticaria, and age of patients with thalassemia (P < .05). Children without thyroid abnormalities were more likely to have xerosis, pruritus, idiopathic guttate hypomelanosis, urticaria, and ephelides (86%) than controls (P < .05). Although there was no significant difference in skin findings between patients who did and did not receive chelating agents (P > .05), a significant association was found between xerosis and the use of deferoxamine and deferiprone, whereas ephelides and urticaria were more common in patients receiving deferasirox.Conclusion: Because cutaneous manifestations are common in Egyptian patients with beta thalassemia major, regular dermatologic follow‐up is recommended for early management.Keywords
This publication has 9 references indexed in Scilit:
- Skin Disorders in Egyptian Children with β-Thalassemia MajorJournal of Tropical Pediatrics, 2017
- Clinical profile of cutaneous manifestations with and without hematologic disease: A comparative studyIndian Dermatology Online Journal, 2014
- Efficacy of Deferasirox in North Indian β-Thalassemia Major PatientsJournal of Pediatric Hematology/Oncology, 2012
- Skin diseases in patients with β‐thalassemia majorInternational Journal of Dermatology, 2009
- Hemoglobinopathy Control Program in TurkeyPublic Health Genomics, 2006
- Longitudinal Study on Thyroid Function in Patients with Thalassemia MajorJournal of Pediatric Endocrinology and Metabolism, 2006
- ThalassemiaHematology-American Society Hematology Education Program, 2004
- Continuous low-dose subcutaneous desferrioxamine (DFO) to prevent allergic manifestations in patients with iron overloadAnnals of Hematology, 1996
- Idiopathic guttate hypomelanosisBritish Journal of Dermatology, 1980